Google DeepMind's moonshot, Isomorphic Labs, is gearing up to launch its first ever human trial of AI-designed drugs. The ...

Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 ...

Alphabet’s Isomorphic Labs is preparing to begin human trials of a drug designed using AI, based on protein modelling ...

One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to ...

Founded in 2021, Isomorphic Labs is a subsidiary of Google parent Alphabet. It is currently preparing to dose the first patients with the AI-engineered drug in clinical trials and is “staffing up” ...

Google DeepMind CEO Demis Hassabis has said that AI can have a serious crack at solving all diseases in the coming years. And ...

Google DeepMind's drug discovery company, Isomorphic Labs, is gearing up to launch the human trials of its AI-designed drugs.

Out to make a bigger difference, Alphabet’s Isomorphic Labs is exploring a much more useful application of AI. The Google ...

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are ...

Google DeepMind's Isomorphic Labs is set to begin human trials of drugs designed by artificial intelligence, marking a ...

Now Google’s DeepMind division says it’s made a leap in trying to understand the code with AlphaGenome, an AI model that ...

Isomorphic Labs was spun out of Google DeepMind, after the tech giant achieved one of the biggest biological breakthroughs in the last 50 years. ...